Cargando…
BNT162b2 (Pfizer/BioNTech) COVID-19 Vaccination Was Not Associated with the Progression of Activity of the Exudative Form of Age-Related Macular Degeneration during Anti-VEGF Therapy
Background: Evaluation of the activity of the exudative form of age-related macular degeneration (AMD) during anti-vascular endothelial growth factor (anti-VEGF) therapy before and after administration of BNT162b2 (Pfizer/BioNTech) vaccination. Methods: The optical coherence tomography and best corr...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696807/ https://www.ncbi.nlm.nih.gov/pubmed/36366385 http://dx.doi.org/10.3390/vaccines10111878 |
_version_ | 1784838399879806976 |
---|---|
author | Płatkowska-Adamska, Bernadetta Bociek, Agnieszka Krupińska, Joanna Kal, Magdalena Biskup, Michał Zarębska-Michaluk, Dorota Odrobina, Dominik |
author_facet | Płatkowska-Adamska, Bernadetta Bociek, Agnieszka Krupińska, Joanna Kal, Magdalena Biskup, Michał Zarębska-Michaluk, Dorota Odrobina, Dominik |
author_sort | Płatkowska-Adamska, Bernadetta |
collection | PubMed |
description | Background: Evaluation of the activity of the exudative form of age-related macular degeneration (AMD) during anti-vascular endothelial growth factor (anti-VEGF) therapy before and after administration of BNT162b2 (Pfizer/BioNTech) vaccination. Methods: The optical coherence tomography and best corrected visual acuity (BCVA) records of the two previous visits before the first dose of BNT162b2 (first pre-vaccination visit marked as “V-1”, the previous pre-vaccination “V-2”), and two subsequent visits after the second dose of vaccination (first visit after the second dose marked as “V1”, second visit after the second dose marked as “V2”) were collected for 63 eyes of 59 patients. Results: The difference in the average retinal thickness was observed between the last and each other checkpoint for the aflibercept group and in the overall outcome. The maximum thickness from the inner retinal surface to the inner border of RPE decreased during the observation; differences were observed comparing visits −2 and 1. Subretinal complex thickness decreased during follow-up, and the differences were observed between visits −2 and 2. There were no statistically significant differences in the BCVA and the occurrence of intraretinal cystoid fluid, serous PED, subretinal hyperreflective material, and retinal hemorrhage. Conclusion: In the present study, the activity of the exudative form of AMD did not deteriorate after the administration of the BNT162b2 vaccine. |
format | Online Article Text |
id | pubmed-9696807 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96968072022-11-26 BNT162b2 (Pfizer/BioNTech) COVID-19 Vaccination Was Not Associated with the Progression of Activity of the Exudative Form of Age-Related Macular Degeneration during Anti-VEGF Therapy Płatkowska-Adamska, Bernadetta Bociek, Agnieszka Krupińska, Joanna Kal, Magdalena Biskup, Michał Zarębska-Michaluk, Dorota Odrobina, Dominik Vaccines (Basel) Article Background: Evaluation of the activity of the exudative form of age-related macular degeneration (AMD) during anti-vascular endothelial growth factor (anti-VEGF) therapy before and after administration of BNT162b2 (Pfizer/BioNTech) vaccination. Methods: The optical coherence tomography and best corrected visual acuity (BCVA) records of the two previous visits before the first dose of BNT162b2 (first pre-vaccination visit marked as “V-1”, the previous pre-vaccination “V-2”), and two subsequent visits after the second dose of vaccination (first visit after the second dose marked as “V1”, second visit after the second dose marked as “V2”) were collected for 63 eyes of 59 patients. Results: The difference in the average retinal thickness was observed between the last and each other checkpoint for the aflibercept group and in the overall outcome. The maximum thickness from the inner retinal surface to the inner border of RPE decreased during the observation; differences were observed comparing visits −2 and 1. Subretinal complex thickness decreased during follow-up, and the differences were observed between visits −2 and 2. There were no statistically significant differences in the BCVA and the occurrence of intraretinal cystoid fluid, serous PED, subretinal hyperreflective material, and retinal hemorrhage. Conclusion: In the present study, the activity of the exudative form of AMD did not deteriorate after the administration of the BNT162b2 vaccine. MDPI 2022-11-07 /pmc/articles/PMC9696807/ /pubmed/36366385 http://dx.doi.org/10.3390/vaccines10111878 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Płatkowska-Adamska, Bernadetta Bociek, Agnieszka Krupińska, Joanna Kal, Magdalena Biskup, Michał Zarębska-Michaluk, Dorota Odrobina, Dominik BNT162b2 (Pfizer/BioNTech) COVID-19 Vaccination Was Not Associated with the Progression of Activity of the Exudative Form of Age-Related Macular Degeneration during Anti-VEGF Therapy |
title | BNT162b2 (Pfizer/BioNTech) COVID-19 Vaccination Was Not Associated with the Progression of Activity of the Exudative Form of Age-Related Macular Degeneration during Anti-VEGF Therapy |
title_full | BNT162b2 (Pfizer/BioNTech) COVID-19 Vaccination Was Not Associated with the Progression of Activity of the Exudative Form of Age-Related Macular Degeneration during Anti-VEGF Therapy |
title_fullStr | BNT162b2 (Pfizer/BioNTech) COVID-19 Vaccination Was Not Associated with the Progression of Activity of the Exudative Form of Age-Related Macular Degeneration during Anti-VEGF Therapy |
title_full_unstemmed | BNT162b2 (Pfizer/BioNTech) COVID-19 Vaccination Was Not Associated with the Progression of Activity of the Exudative Form of Age-Related Macular Degeneration during Anti-VEGF Therapy |
title_short | BNT162b2 (Pfizer/BioNTech) COVID-19 Vaccination Was Not Associated with the Progression of Activity of the Exudative Form of Age-Related Macular Degeneration during Anti-VEGF Therapy |
title_sort | bnt162b2 (pfizer/biontech) covid-19 vaccination was not associated with the progression of activity of the exudative form of age-related macular degeneration during anti-vegf therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696807/ https://www.ncbi.nlm.nih.gov/pubmed/36366385 http://dx.doi.org/10.3390/vaccines10111878 |
work_keys_str_mv | AT płatkowskaadamskabernadetta bnt162b2pfizerbiontechcovid19vaccinationwasnotassociatedwiththeprogressionofactivityoftheexudativeformofagerelatedmaculardegenerationduringantivegftherapy AT bociekagnieszka bnt162b2pfizerbiontechcovid19vaccinationwasnotassociatedwiththeprogressionofactivityoftheexudativeformofagerelatedmaculardegenerationduringantivegftherapy AT krupinskajoanna bnt162b2pfizerbiontechcovid19vaccinationwasnotassociatedwiththeprogressionofactivityoftheexudativeformofagerelatedmaculardegenerationduringantivegftherapy AT kalmagdalena bnt162b2pfizerbiontechcovid19vaccinationwasnotassociatedwiththeprogressionofactivityoftheexudativeformofagerelatedmaculardegenerationduringantivegftherapy AT biskupmichał bnt162b2pfizerbiontechcovid19vaccinationwasnotassociatedwiththeprogressionofactivityoftheexudativeformofagerelatedmaculardegenerationduringantivegftherapy AT zarebskamichalukdorota bnt162b2pfizerbiontechcovid19vaccinationwasnotassociatedwiththeprogressionofactivityoftheexudativeformofagerelatedmaculardegenerationduringantivegftherapy AT odrobinadominik bnt162b2pfizerbiontechcovid19vaccinationwasnotassociatedwiththeprogressionofactivityoftheexudativeformofagerelatedmaculardegenerationduringantivegftherapy |